NCT06867419Recruiting
Metabolic Features Effects on FAST Score in MASLD Patients
Metabolic Features Effect on FibroScan-AST (FAST) Score in Egyptian Patients With Metabolic-Associated Steatotic Liver Disease (MASLD)
Source: ClinicalTrials.gov · Last updated 10 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this observational cross-sectional study is to evaluate the effect of metabolic features on Fibroscan-AST (FAST) score stratification in metabolic dysfunction-associated steatotic liver disease (MASLD) patients in Egypt. Researchers will identify the metabolic risk factors in patients with MASLD. evaluate the effect of metabolic features on stratifying MASLD patients by predicting higher FAST score. Participants will be subjected to history taking, clinical examination, laboratory investigations, abdominal ultrasonography, and transient elastography (Fibroscan) to measure liver stiffness (LSM) and controlled attenuation parameter (CAP). The Non-alcoholic fatty liver disease (NAFLD) fibrosis score and FAST score will be calculated.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 385 (estimated)
- First submitted
- 13 Feb 2025
- Start date
- 1 Sept 2024
- Primary completion date
- 30 Mar 2025
- Lead sponsor
- Tanta University
- Diseases
- Fatty liver disease (MASLD/MASH)
- NCT number
- NCT06867419
What you commit to
- Study type: Observational
- Planned participants: 385
- From 1 Sept 2024 to the primary completion date, 30 Mar 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with a history of significant alcohol consumption more than 30 g/day in men and \> 20 g/day in women.
- Patients with positive hepatitis B or C virus markers.
- Patients with autoimmune hepatitis.
- Patients with any other metabolic liver disease.
Other
- Patients with hepatic focal lesions.
Who the study is looking for
- All patients with MASLD who had steatosis detected by (VCTE-CAP) elastography
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tanta University Hospitals Coordinator of this site? Confirm its status | Tanta | Egypt | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.